| abstract |
Disclosed is a novel pyrazolyl 5-thio-β-D-glucopyranoside compound which can inhibit the SGLT1 activity selectively and can prevent the absorption of glucose through the digestive tract, thereby controlling the IGT (impaired glucose tolerance). Specifically, disclosed is a pyrazolyl 5-thioglucoside compound represented by the formula (I), a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt. [Chemical formula] wherein Z represents a C1-6 alkyl group; R1, R2 and R3 independently represent a hydrogen atom, a halogen atom, a C1-6 alkoxy group or a C1-6alkyl group; Y represents a single bond, a C1-6 alkylene group, a C2-6 alkenylene group or –O-(CH2)n- [wherein n represents an integer ranging from 1 to 4]; and Q represents a hydroxyl group, -OC1-4-alkylphenyl, -N(RA)RB or –CONHRC. |